View Older Stories View More Recent Stories

Sep 8, 2021 09:00AM Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
Sep 7, 2021 09:00AM Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
Aug 9, 2021 04:01PM Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
Aug 3, 2021 07:29AM Arcturus Therapeutics (ARCT) Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165
Aug 3, 2021 07:00AM Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 St
Aug 2, 2021 09:03AM Arcturus Therapeutics (ARCT) Announces Approval of Clinical Trial Application to Advance ARCT-154, a Next Generation STARR mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Con
Aug 2, 2021 09:00AM Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
Aug 2, 2021 07:03AM Arcturus Therapeutics (ARCT) Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
Aug 2, 2021 07:00AM Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
Jul 28, 2021 08:32AM Arcturus Therapeutics (ARCT) Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
Jul 28, 2021 08:30AM Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Jul 26, 2021 04:01PM Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
Jul 6, 2021 09:00AM Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
Jun 9, 2021 09:00AM Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
May 10, 2021 04:01PM Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
May 3, 2021 08:30AM Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
Mar 30, 2021 08:30AM Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
Mar 1, 2021 04:01PM Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
Feb 22, 2021 08:04AM Arcturus Therapeutics (ARCT) Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals (ALXN)
Feb 22, 2021 08:00AM Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
Feb 19, 2021 08:00AM Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021
Feb 11, 2021 08:30AM Arcturus Therapeutics to Present at Upcoming Investor Conferences
Jan 6, 2021 08:00AM Arcturus Therapeutics to Present at Upcoming Investor Conference
Jan 4, 2021 07:02AM Arcturus Therapeutics (ARCT) Granted FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in U.S.
Jan 4, 2021 07:01AM Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
Dec 30, 2020 07:04AM Arcturus Therapeutics (ARCT) Selects ARCT-032 as Development Candidate for Cystic Fibrosis Lung Disease
Dec 30, 2020 07:00AM Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
Dec 28, 2020 04:02PM Arcturus Therapeutics (ARCT) Granted Approval from Singapore Health Sciences Authority to Proceed with Ph. 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate;
Dec 28, 2020 04:01PM Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Pre
Dec 8, 2020 06:05AM Arcturus Therapeutics (ARCT) Prices 1.365M Share Common Offering at $110/Sh
Dec 7, 2020 11:30PM  Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Dec 7, 2020 04:34PM Arcturus Therapeutics (ARCT) Announces Proposed Public Offering of Common Stock
Dec 7, 2020 04:33PM Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
Dec 7, 2020 07:00AM Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency
Nov 30, 2020 06:00PM Arcturus Therapeutics to Present at Upcoming Investor Conference
Nov 9, 2020 04:01PM Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data
Nov 9, 2020 07:00AM Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitment
Nov 4, 2020 08:00AM Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
Oct 30, 2020 09:00AM Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
Oct 5, 2020 08:01AM Arcturus Therapeutics (ARCT) Reports Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810,
Oct 5, 2020 08:00AM Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Oct 1, 2020 08:00AM Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference
View More Recent Stories View Older Stories